The Immune Response Corporation Receives Nasdaq Delisting Notice

Quotations on the Company's common stock are expected to appear inthe "Pink Sheets." The trading symbol for its common stock will remainIMNR. The Company's common stock may also be quoted in the future onthe OTC Bulletin Board ("OTCBB") provided a market maker files thenecessary application with the NASD and such application is cleared.The Company will disclose further trading venue information for itscommon stock when such information becomes available.

About The Immune Response Corporation

The Immune Response Corporation (Nasdaq:IMNR) is abiopharmaceutical company dedicated to becoming a leading immune-basedtherapy company in HIV and MS. The Company's HIV products are based onits patented whole inactivated virus technology, co-invented byCompany founder Dr. Jonas Salk to stimulate HIV immune responses.REMUNE(R), currently in Phase II clinical trials, is being developedas a first-line treatment for people with early-stage HIV. We haveinitiated development of a new immune-based therapy, IR103, whichincorporates a Toll-like receptor (TLR) agonist-based adjuvant and iscurrently in Phase I/II clinical trials in Canada, Italy and theUnited Kingdom.

The Immune Response Corporation is also developing an immune-basedtherapy for MS, NeuroVax(TM), which is currently in Phase II clinicaltrials and has shown potential therapeutic value for thisdifficult-to-treat disease.

Please visit The Immune Response Corporation at www.imnr.com

About Pink Sheets LLC

Pink Sheets provides broker/dealers, issuers and investors withelectronic and print products and information services designed toimprove the transparency of the over-the-counter (OTC) markets. Theproducts are designed to increase the efficiency of OTC markets,leading to greater liquidity and investor interest in OTC securities.Pink Sheets centralized information network is a source of competitivemarket maker quotations, historical prices and corporate informationabout OTC issues and issuers. Pink Sheets is neither a Securities andExchange Commission (SEC) Registered Stock Exchange nor a NASDBroker/Dealer. Investors must contact a NASD Broker/Dealer to trade ina security quoted on the Pink Sheets. Pink Sheets LLC is a privatelyowned company headquartered in New York City. More information isavailable at http://www.pinksheets.com

About the OTC Bulletin Board (OTCBB)

The OTC Bulletin Board (OTCBB) is a regulated quotation servicethat displays real-time quotes, last-sale prices, and volumeinformation in OTC equity securities. OTCBB securities includenational, regional, and foreign equity issues, warrants, units, ADRs,and Direct Participation Programs (DPPs). More information isavailable at http://www.otcbb.com.

This news release contains forward-looking statements.Forward-looking statements are often signaled by forms of words suchas should, could, will, might, plan, projection, forecast, expect,guidance, potential and developing. Actual results could varymaterially from those expected due to a variety of risk factors,including whether the Company will continue as a going concern andsuccessfully raise proceeds from financing activities sufficient tofund operations and additional clinical trials of REMUNE(R),NeuroVax(TM) or IR103, the uncertainty of successful completion of anysuch clinical trials, the fact that the Company has not succeeded incommercializing any drug, the risk that REMUNE(R), NeuroVax(TM) orIR103 might not prove to be effective as either a therapeutic orpreventive vaccine, whether future trials will be conducted andwhether the results of such trials will coincide with the results ofREMUNE(R), NeuroVax(TM) or IR103 in preclinical trials and/or earlierclinical trials, and any transition issues related to the hiring ofJoseph F. O'Neill as Chief Executive Officer. A more extensive set ofrisks is set forth in The Immune Response Corporation's SEC filingsincluding, but not limited to, its Annual Report on Form 10-K for theyear ended December 31, 2004, and its subsequent Quarterly Reportsfiled on Form 10-Q. The Company undertakes no obligation to update theresults of these forward-looking statements to reflect events orcircumstances after today or to reflect the occurrence ofunanticipated events.

REMUNE(R) is a registered trademark of The Immune ResponseCorporation. NeuroVax(TM) is a trademark of The Immune ResponseCorporation.